Thus, our data suggest that compounds affecting NaV1.1 channels in Aδ-fibers of peripheral nerves in a mutation-specific manner, may be a promising avenue for novel type analgesic anti-migraine therapy. The gene discussed is SCN1A; the disease is migraine disorder.